<DOC>
	<DOC>NCT00802139</DOC>
	<brief_summary>multi-center, prospective, randomized, open-labeled, active-drug-controlled, two-parallel-group-comparison(venoferrun group vs Bolgre group)study</brief_summary>
	<brief_title>Efficacy and Safety Study of Iron Sucrose and Oral Iron Acetyl-transferrin Hydroglycerin</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia, Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide, saccharated</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>30~32nd weeks pregnant women aged over 18 years Women who have Hb level of more than 10.0g/dL a week before study initiation Patients who agree to participate in this study in writing Patients who have participated in another clinical study in recent 3 months Patients who are prone to acute hemorrhage during pregnancy Patients who have shown intolerance to iron therapy Hemolytic anemia, hemoglobinopathies (thalassemia, sickle cell) Bleeding tendency, hypersplenism Chronic heart failure, Class IIIV heart disease, uncontrolled arterial hypertension (DBP â‰¥ 115mmHg), deep vein thrombosis, thrombocytosis, chronic renal disease Severe renal failure patients (2.5 times or more higher plasma creatinine level than high limit of normal state) Patients with severe liver dysfunction (2.5 times or more higher AST or ALT than high limit of normal state) Patients with doubled or more CK level than high limit of normal state Patients who are regarded as ineligible for this study by investigator</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>iron deficiency anemia</keyword>
	<keyword>pregnant women with iron deficiency anemia</keyword>
</DOC>